Kiçük hücreli dışı akciğer karsinomlarında nükleer faktör kappa B İmmünohistokimyasal ekspresyonunun prognozla ilişkisi

Amaç: Son dönemde tanımlanan bir transkripsiyon faktörü olan Nükleer Faktör kappa B (NF-kB) ile ilgili literatürde çok sayıda çalışma bulunmaktadır. Bu çalışmalarda çeşitli tümörlerde immünhistokimya ile nükleer ve/veya sitoplazmik boyanmanın olduğu ve hasta prognozu ile ilişki gösterdiği ileri sürülmektedir. Çalısmamızda NF-kB ekspresyonunun küçük hücreli dışı akciğer karsinomlarırida prognoz ile ilişkisini araştırmayı amaçladık. Gereç ve Yöntem: Çalışmamızda bu protein ailesinin iki önemli üyesi olan p50 ve p65'in (RelA) 30'u klinik izlemli 52 küçük hücreli dışı akciğer karsinomu hastasmdaki immünhistokimyasal ekspresyonunu ve bunun prognozla ilişkisini inceledik. Bulgular: Çeşitli histopatolojik tanı gruplarındaki olgular immünhistokimyasal olarak p50 ve p65 ile yüksek oranda sitoplazmik ekspresyon göstermiştir. Nükleer boyanma düşük oranda saptanmıştır. Her iki antikor ile klinik parametreler ve sağkalım arasında istatistiksel olarak anlamlı sonuç elde edilememiştir. p50 ve p65'in hem nükleer hem sitoplazmik boyanma yoğunluk ve yaygınlıkları arasında ise anlamlı pozitif korelasyon saptanmıştır. Sonuç: Küçük hücreli dışı akciğer karsinomları immünhistokimyasal olarak NF-kB p50 ve p65 komponentlerini yüksek oranda eksprese etmektedir. Ancak bu ekspresyon prognostik faktörlerle ilişkili bulunmamıştır.

Prognostic significance of nuclear factor kappa B immunohistochemical expression in non-small cell lung carcinomas

Purpose: To investigate the immunohistochemical expression and the prognostic significance in non-small cell lung carcinomas of a recently defined. transcription factor, Nuclear Factor kappa B (NF-kB), which has been reported to be expressed in the nucleus and/or cytoplasm by a variety of neoplasms in the literature. Materials and Methods: Immunohistochemistry against the two major components of this protein family, p50 and p65 (RelA), was performed on 52 patients' material diagnosed as non-small cell lung carcinoma, for 30 of which we had the clinical follow-up data. Results: We observed a high rate of cytoplasmic p50 and p65 expression in all different lung carcinoma histological subtypes. Nuclear staining was only found in a few cases. There was no statistical significance'between staining rates and clinical parameters or patient survival. A positive correlation was shown between nuclear and cytoplasmic staining rates of both p50 and p65. Conclusion: Non-small cell lung carcinomas highly express NF-kB p50 and p65 components immunohistochemically. Nevertheless, this expression does not significantly affect prognosis.

PDF

___

1. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancerbinding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-928.
2. Shishodia S, Aggarwal BB. Nuclear Factor-kB: a friend or a foe in cancer? Biochem Pharmacol 2004; 68: 1071-1080.
3. Karin M, Delhause M. The IkB kinase (IKK) and NF-kB: key elements of proinflammatory signalling. Semin Immunol 2000; 12: 85- 98.
4. Garg A, Aggerwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002; 16: 1053-1068.
5. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-888.
6. Jones DR, Broad RM, Corneau LD, et al. Inhibition of nuclear factor kB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J Thorac Cardiovasc Surg 2002; 123:310-317.
7. Rundall BK, Denlinger CE, Jones DR. Combined histone deacetylase and NF-kB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004; 136: 416-425.
8. Beg AA, Sha WC, Bronstön RT, Ghosh S, et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NFkB. Nature 1995; 376: 167-170.
9. Sovak M, Bellas RE, Kim DW, et al. Aberrant Nuclear Factor-kB/ Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100: 2952-2960.
10. Biswas DK, Shi Q, Baily S, et al. NF-kB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc NatlAcadSciUSA2004; 101: 10137-10142.
11. Wang T, Wang Y, Wu MC, et al. Activating mechanism of transcriptor NF-kappaB regulated by hepatitis B virus X protein in hepatocellular carcinoma. World J Gastroenterol 2004; 10: 356-360.
12. Ondrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF-kB, AP-1 and NF-kB-IL6 in human head and neck squamous cell carcinoma cell lines that express proinflammatory and pro-angiogenic cytokines. Mol Carcinog 1999; 26: 119-129.
13. Yamanaka N, Sasaki N, Tasaki A, et al. Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res 2004; 24: 1071-1075.
14. Yang GF, Deng CS, Xiong YY, et al. Expression of nuclear factorkappa B and target genes in gastric precancerous lesions and adenocarcinoma: Association with Helicobacter pylori cagA (+) infection. World J Gastroenterol 2004; 10: 491-496.
15. Pallares J, Martinez-Guitarte JL, Dolcet X, et al. Abnormalities in the NF-kB family and related proteins in endometrial carcinoma. J Pathol 2004; 204: 569-577.
16. Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-127.
17. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kb p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003; 63: 8293-8301.
18. Shukla S, MacLennan GT, Fu P, et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004; 6: 390- 400.
19. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, et al. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004; 10: 5501-5507.
20. Oya M, Takayanagi A, Horiguchi A, et al. Increased nuclear factorkB activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003; 24: 377-384.
21. Nair A, Venkatraman M, Maliekal TT, et al. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 2003; 22: 50-58.
22. Prusty BK, Husain SA, Das BC. Constitutive activation of nuclear factor -kB: preferential homodimerization of p50 subunits in cervical carcinoma. Front Biosci 2005; 10: 1510-1519.
23. Kojima M, Morisaki T, Sasaki N, et al. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 2004; 24: 675-681.
24. Ismail HA, Lessard L, Mes-Masson AM, et al. Expression of NF-kB in prostate cancer lymph node metastases. Prostate 2004; 58: 308- 313.
25. Rayet B, Gelinas C. Aberrant rel/NF-kB genes and activity in human cancer. Oncogene 1993; 18: 6938-6947.
26. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell 2002; 109: S81-S96.
27. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, et al. Inducible nuclear expression of newly synthesized IkB alpha negatively regulates DNA-binding and transcriptional activities of NF-kB. Mol Cell BİOİ1995; 15:2689-2696.
28. Malek S, Chen Y, Huxford T, et al. IkB beta, but not IkB alpha, functions as a classical cytoplasmic inhibitor of NF-kB dimers by masking both NF-kB nuclear localization sequences in resting cells. J Biol Chem 2001; 276: 45225-45235.Ekinci